摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-5-isoquinolinylurea | 581809-69-0

中文名称
——
中文别名
——
英文名称
N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-5-isoquinolinylurea
英文别名
1-[[3-Fluoro-4-(trifluoromethyl)phenyl]methyl]-3-isoquinolin-5-ylurea
N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-5-isoquinolinylurea化学式
CAS
581809-69-0
化学式
C18H13F4N3O
mdl
——
分子量
363.314
InChiKey
SRCJYDJMMNVROZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    26
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    54
  • 氢给体数:
    2
  • 氢受体数:
    6

文献信息

  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    申请人:——
    公开号:US20040157849A1
    公开(公告)日:2004-08-12
    Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
    式(I)的化合物是新颖的VR1拮抗剂,可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
  • [EN] FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR<br/>[FR] COMPOSES AZABICYCLIQUES FUSIONNES QUI INHIBENT LE RECEPTEUR (VR1) SOUS-TYPE 1 DU RECEPTEUR VANILLOIDE
    申请人:ABBOTT LAB
    公开号:WO2003070247A1
    公开(公告)日:2003-08-28
    Compounds of formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
    化学式为(I)的化合物是新颖的VR1拮抗剂,可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
  • Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
    申请人:——
    公开号:US20040209884A1
    公开(公告)日:2004-10-21
    Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
    式(I)1的化合物是一种新型的VR1拮抗剂,可用于治疗疼痛、炎性热性过敏、尿失禁和膀胱过度活动。
  • Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain
    申请人:Brown Elizabeth Rebecca
    公开号:US20050107388A1
    公开(公告)日:2005-05-19
    The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilising them.
    本发明提供了式(I)的化合物;其药学上可接受的盐和N-氧化物,其中A,B,D和E是C或N,但其中一个或多个是N,R1,R2,R3,R4,R5和R6是简单的取代基,n是0-3,y是芳基,杂环芳基,碳环芳基或融合的碳环芳基基团;作为VR-1拮抗剂,用于治疗疼痛和/或炎症占优势的疾病或症状;同样的用于制造药物、包含它们的制剂和利用它们的治疗方法。
  • FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    申请人:LEE CHIH-HUNG
    公开号:US20080214524A1
    公开(公告)日:2008-09-04
    Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
    公式(I)的化合物是新型的VR1拮抗剂,可用于治疗疼痛、炎症性热痛敏、尿失禁和膀胱过度活动。
查看更多